The Tirzepatide Telehealth Market

Who left during 2026

Five of the largest names on this site no longer sell compounded tirzepatide. Ro and the WeightWatchers clinic carry brand-name products with membership billed separately. Hims closed its compounded programme to new patients after a March 2026 settlement. Calibrate operates a brand-only membership model. Noom's published figures describe brand Zepbound.

That matters for anyone reading an older comparison. A list ranking those companies for compounded tirzepatide is describing a product they do not sell, and the verification date is the only way to tell. It also means the cheap end of this market is now served by smaller operators with far less brand recognition, which raises the value of verifying the pharmacy rather than trusting the name.

The shape of the market

We track 32 tirzepatide telehealth programmes. 17 publish a price we could capture. All-in cost at a 10 mg maintenance dose runs from $215 to $548 for the identical molecule from the same category of licensed pharmacy.

That spread is not explained by the medicine. It is overhead, clinical wrap, pharmacy sourcing and margin.

Two pricing models, one of them dominant

11 of the 17 priced programmes hold one price at every strength; the rest reprice as the dose climbs. The second group's advertised figure describes roughly four weeks of a twelve-month course.

Fee structures fragment the comparison

6 programmes charge a mandatory recurring fee on top of medication. Comparisons quoting medication alone understate those programmes by the full membership, permanently.

Disclosure is the exception

Fewer than a fifth of priced programmes identify the dispensing pharmacy before purchase. That single disclosure is the one that lets a patient check a state board register, and it costs a programme nothing to publish.

What we could not establish

Shipping reliability, response times, clinical quality, or how any programme behaves when something goes wrong. None of it is measurable from outside, so none of it is in our tables.

Why this distinction changes what you pay

Every structural difference in this market resolves into money at a maintenance dose. Whether a programme charges a membership, whether it reprices with the dose, whether it demands a term, and whether it bundles or splits its charges together account for most of the gap between the cheapest tracked first year at $2,580 and the most expensive.

None of those differences is visible in an advertised headline figure, which is the reason this site exists in the form it does.

How to act on it this week

Price the dose you expect to maintain on rather than the starter dose. Add every recurring fee. Ask whether the quoted rate holds at renewal. Establish who compounds the medicine. And do not enter a prepaid term until you have held a maintenance dose for a cycle.

Those five steps take under an hour and reliably beat any amount of comparison reading, because they surface the information that comparison tables omit.

How this connects to what you will actually pay

Everything in this section resolves to one number: the all-in monthly cost at the dose you end up holding. Across the 17 programmes we price, that runs from $215 at the cheapest tracked route to several times that at the most expensive, for the identical molecule from the same category of licensed pharmacy.

6 of those programmes charge a recurring platform fee on top of medication and 11 hold one price at every strength. Those two facts explain most of the spread between advertised prices and real ones.

What we could verify and what we could not

11 of 32 tracked programmes have a price we read at the provider or manufacturer. The rest carry third-party figures we have not confirmed, or publish nothing we can interpret. Every table on this site marks which is which, and the comparison matrix lets you filter to verified prices only.

Where we have checked a third-party figure against a provider's own page, it has almost always moved — and it has moved upward. Promotional first months, prepaid bundle rates and medication-only figures that exclude memberships are all published as ongoing all-in prices. Assume an unverified figure is optimistic.

The regulatory distinction that sits under all of this

Compounded tirzepatide is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. The active molecule is the same as the branded product; the pre-market review is not, and the assurance comes instead from the pharmacy, the state board that licenses it and, at good operations, batch sterility and potency testing.

That is a legitimate framework rather than a loophole, and it is also why the price is lower. It puts more of the verification burden on the patient, which is the honest trade being made.

Method

Computed over one file covering 32 programmes on a single price basis: all-in monthly cost, medication plus any recurring fee, at a named dose tier. No estimates, no imputed values, and no programme excluded for reasons other than the criterion stated.

Where a finding depends on a figure we could not verify at source, it is flagged rather than rounded away.

Findings

All-in cost at a 10 mg maintenance dose spans $215 to $548 — a 2.5-times spread for the identical molecule from the same category of licensed pharmacy. 11 of 17 programmes hold one price at every dose; the rest reprice as you climb. 6 charge a mandatory recurring fee on top of medication.

Fewer than a fifth identify the dispensing pharmacy before purchase, which is the single disclosure that would let a patient verify anything independently.

Limitations

Everything here comes from published material we could access. We did not enrol, did not mystery-shop, and did not contact programmes for comment before publication. Service quality, shipping reliability and clinical depth are absent because they are not measurable from outside.

A programme that discloses something we could not find should tell us, and the record will be corrected with the date.

Reuse

Cite freely with attribution and the capture date. Journalists and analysts should take the underlying file rather than transcribing from a table, because the file carries the evidence status that a table necessarily compresses.